EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nanostructured Lipid Carriers for Enhancement of Oral Delivery of Ebastine: In Vitro and In Vivo Investigation

Samar H. Faheim, Hajar Alghamdi, Reem M. Abuhejail, Abdullah Abdulrahman Aljasser, Asmaa A. Hedaya, Amal A. Sultan

Pharmaceuticals · 12.11.2026 · 19 (11) · 1796

DOI: 10.3390/ph19111796 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 12.11.2026. Verfasst von Samar H. Faheim und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Ebastine is a second-generation non-sedative antihistamine with potent anti-inflammatory activity. The therapeutic efficacy of ebastine is limited by its low water solubility. Accordingly, this study aimed to formulate nano lipid-based systems to enhance the anti-inflammatory potential of ebastine.

Methods

Nanostructured lipid carriers (NLCs) loaded with ebastine were formulated using the micro-emulsification technique. The prepared systems were characterized for particle size (PS), zeta potential (ZP), morphological features using transmission electron microscopy (TEM), entrapment efficiency (%EE), and in vitro drug release. The in vivo anti-inflammatory efficacy was also evaluated employing the carrageenan-induced paw edema model.

Results

The constructed NLCs demonstrated negatively charged spherical nanoparticles with average particle sizes ranging from 146.7 nm to 293.0 nm. Ebastine was effectively trapped in the NLCs, with the recorded %EE ranging from 96.4% to 97.5%. All the fabricated NLCs revealed a sustained ebastine release behavior over 8 h compared to the aqueous drug dispersion. In vivo performance evaluations demonstrated a significant improvement in the anti-inflammatory efficacy of ebastine-loaded NLCs compared to unprocessed ebastine aqueous dispersion. This was manifested in the significant reduction of the rats’ paw edema, with the % edema inhibition reaching 31.3%, 40.2%, and 35.2% for F1, F2, and F3, respectively. However, without a blank NLC control, the isolated effect of ebastine could not be fully distinguished from that of the carrier. Additionally, histopathological examinations revealed a remarkable reduction in the inflammation score in thin and thick skin sections for NLC groups compared to the untreated negative control group. Notably, F2 and F3 showed significant improvement in thin-skin inflammation scores.

Conclusions

The tested NLCs potentially demonstrated an improved anti-inflammatory efficiency compared to the free drug. The overall findings introduced NLCs as a promising nanoplatform for enhancing the pharmacodynamic efficacy of ebastine.

Zitieren

APA

Faheim, S. H., Alghamdi, H., Abuhejail, R. M., Aljasser, A. A., Hedaya, A. A., & Sultan, A. A. (2026). Nanostructured Lipid Carriers for Enhancement of Oral Delivery of Ebastine: In Vitro and In Vivo Investigation. Pharmaceuticals, 19(11), 1796. https://doi.org/10.3390/ph19111796

Vancouver

Faheim SH, Alghamdi H, Abuhejail RM, Aljasser AA, Hedaya AA, Sultan AA. Nanostructured Lipid Carriers for Enhancement of Oral Delivery of Ebastine: In Vitro and In Vivo Investigation. Pharmaceuticals. 2026;19(11):1796. doi:10.3390/ph19111796

BibTeX
@article{Faheim2026,
  author = {Faheim, Samar H. and Alghamdi, Hajar and Abuhejail, Reem M. and Aljasser, Abdullah Abdulrahman and Hedaya, Asmaa A. and Sultan, Amal A.},
  title = {Nanostructured Lipid Carriers for Enhancement of Oral Delivery of Ebastine: In Vitro and In Vivo Investigation},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1796},
  doi = {10.3390/ph19111796}
}
Kostenlos starten →